Do changes in antimicrobial resistance necessitate reconsideration of surgical antimicrobial prophylaxis strategies?

Surgical Infections

Volumn 10, Issue 6, 2009, Pages 557-562

  Falagas, Matthew E ^a,b,c   Alexiou, Vangelis G ^a   Peppas, George ^a,b   Makris, Gregory C ^a,d  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b Department of Medicine ^*  (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN; COTRIMOXAZOLE; GENTAMICIN; GLYCOPEPTIDE; QUINOLONE; RIFAMPICIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; GRAM NEGATIVE BACTERIUM; HEALTH SURVEY; HEART SURGERY; HOSPITAL ADMISSION; HUMAN; MEDICAL SOCIETY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEUROSURGERY; ORTHOPEDIC SURGERY; PERIOPERATIVE PERIOD; PREVALENCE; PRIORITY JOURNAL; REVIEW; SURGICAL INFECTION; VASCULAR SURGERY;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GUIDELINES AS TOPIC; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STAPHYLOCOCCAL INFECTIONS;

EID: 73849116769     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2008.105     Document Type: Review

References (53)

1. Burke JP. Infection control-a problem for patient safety. N Engl J Med 2003;348:651-656.
2. Tourmousoglou CE, Yiannakopoulou ECh, Kalapothaki V, et al. Adherence to guidelines for antibiotic prophylaxis in general surgery: A critical appraisal. J Antimicrob Chemother 2008;61:214-218.
3. Karchmer AW. Nosocomial bloodstream infections: Organisms, risk factors and implications. Clin Infect Dis 2000; 31(Suppl 4):S139-S143.
4. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteraemia: A meta-analysis. Clin Infect Dis 2003;36:53-59.
5. Athanassa Z, Siempos II, Falagas ME. Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: A systematic review. Eur Respir J 2008;31:625-632.
6. Panlilio AL, Culver DH, Gaynes RP, et al. Methicillinresistant Staphylococcus aureus in US hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992;13:582-586.
7. Nosocomial Infection National Surveillance Service. Surveillance of surgical site infection in English hospitals 1997-2002. London. Public Health Laboratory Service, 2002.
8. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-317.
9. National Nosocomial Infections Surveillance (NNIS) System Report. Data summary from 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-485.
10. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in paediatric patients in United States hospitals: Epidemiology, clinical features, and susceptibilities. Pediatr Infect Dis J 2003;22:686-691. (Pubitemid 36999643)
11. Diekema DJ, Pfaller MA, Schmitz FJ, et al.; SENTRY Participants Group. Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32:S114-S132.
12. Boucher HW, Corey GR. Epidemiology of methicillinresistant Staphylococcus aureus. Clin Infect Dis 2008;46:S344-S349.
13. European Antimicrobial Resistance Surveillance System Annual Report, January 1999-December 2006. EARSS. Bilthoven, The Netherlands, 2007.
14. Falagas ME, Bakossi A, Pappas VD, et al. Secular trends of blood isolates in patients from a rural area population hospitalized in a tertiary center in a small city in Greece. BMC Microbiol 2006;6:41.
15. Hart CA, Kariuki S. Antimicrobial resistance in developing countries. BMJ 1998;317:647-650.
16. Udo EE, Pearman JW, Grubb WB. Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp Infect 1993;25:97-108.
17. Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired methicillin-resistant Staphylococcus aureus: An emerging threat. Lancet Infect Dis 2005;5:275-286.
18. Buescher ES. Community-acquired methicillin-resistant Staphylococcus aureus in pediatrics. Curr Opin Pediatr 2005;17: 67-70.
19. Vandenesch F, Naimi T, Enright MC, et al. Communityacquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: Worldwide emergence. Emerg Infect Dis 2003;9:978-984
20. Klevens RM, Morrison MA, Nadle J, et al.; Active Bacterial Core Surveillance (ABCs) MRSA Investigators. Staphylococcus aureus invasive methicillin-resistant infections in the United States. JAMA 2007;298:1763-1771.
21. Otter JA, French GL. The emergence of communityassociated methicillin-resistant Staphylococcus aureus at a London teaching hospital, 2000-2006. Clin Microbiol Infect 2008;14:670-676.
22. Michalopoulos A, Falagas ME. Multi-systemic methicillinresistant Staphylococcus aureus (MRSA) community-acquired infection. Med Sci Monit 2006;5:CS39-CS43.
23. Reduced susceptibility of Staphylococcus aureus to vancomycin-Japan, 1996. MMWR Morb Mortal Wkly Rep 1997;46:624-626.
24. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999;340:493-501.
25. Rotum SS, McMath V, Schoonmaker DJ, et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from patient with fatal bacteraemia. Emerg Infect Dis 1999; 5:147-149.
26. Staphylococcus aureus with reduced susceptibility to vancomycin-Illinois, 1999. MMWR Morb Mort Wkly Rep 2000;48:1165-1167.
27. Hageman JC, Pegues DA, Jepson C, et al. Vancomycinintermediate Staphylococcus aureus in home health-care patient. Emerg Infect Dis 2001;7:1023-1025.
28. Whitener CJ, Park SY, Browne FA, et al. Vancomycinresistant Staphylococcus aureus in the absence of vancomycin exposure. Clin Infect Dis 2004;38:1049-1055.
29. Siegel JD, Rhinehart E, Jackson M, Chiarello L; Health Care Infection Control Practices Advisory Committee. 2007 Guideline for isolation precautions: Preventing transmission of infectious agents in health care settings. Am J Infect Control 2007;10:S65-S164.
30. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrugresistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003;24:362-386.
31. Engelman R, Shahian D, Shemin R, et al. The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic prophylaxis in cardiac surgery II: Antibiotic choice. Ann Thorac Surg 2007;83:1569-1576.
32. Bratzler DW, Houck PM; Surgical Infection Prevention Guidelines Writers Workgroup. Antimicrobial prophylaxis for surgery: An advisory statement from the National Surgical Infection Prevention Project. Am J Surg 2005;189: 395-404.
33. Finkelstein R, Rabino G, Mashiah T, et al. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg 2002;123:326-332.
34. Manian FA, Meyer PL, Setzer J, et al. Surgical site infections associated with methicillin-resistant Staphylococcus aureus: Do postoperative factors play a role? Clin Infect Dis 2003; 36:863-868.
35. Gemmell CG, Edwards DI, Fraise AP, et al. on behalf of the Joint Working Party of the British Society for Antimicrobial Chemotherapy, Hospital Infection Society and Infection Control Nurses Association. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006; 58:220.
36. Scottish Intercollegiate Guidelines Network. Antibiotic prophylaxis in surgery. Guideline No. 104. SIGN. Edinburgh, Scotland. July 2008.
37. Perl TM, Cullen JJ, Wenzel RP, et al.; Mupirocin and the Risk of Staphylococcus aureus Study Team. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med. 2002;346:1871-1877.
38. Bolon MK, Morlote M, Weber SG, et al. Glycopeptides are no more effective than beta-lactam agents for prevention of surgical site infection after cardiac surgery: A meta-analysis. Clin Infect Dis 2004;38:1357-1363.
39. Garey KW, Lai D, Dao-Tran TK, et al. Interrupted time series analysis of vancomycin compared to cefuroxime for surgical prophylaxis in patients undergoing cardiac surgery. Antimicrob Agents Chemother 2008;52:446-451.
40. Shime N, Kato Y, Kosaka T, et al. Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice. Eur J Cardiothorac Surg 2007;32:577-581.
41. Dhadwal K, Al-Ruzzeh S, Athanasiou T, et al. Comparison of clinical and economic outcomes of two antibiotic prophylaxis regimens for sternal wound infection in high-risk patients following coronary artery bypass grafting surgery: A prospective randomised double-blind controlled trial. Heart 2007;93:1126-1133.
42. Cranny G, Elliott R, Weatherly H, et al. A systematic review and economic model of switching from non-glycopeptide to glycopeptide antibiotic prophylaxis for surgery. Health Technol Assess 2008;12:1-147.
43. Vardakas KZ, Soteriades ES, Chrysanthopoulou SA, et al. Perioperative anti-infective prophylaxis with teicoplanin compared to cephalosporins in orthopaedic and vascular surgery involving prosthetic material. Clin Microbiol Infect 2005;11:775-777.
44. Roumbelaki M, Kritsotakis EI, Tsioutis C, et al. Surveillance of surgical site infections at a tertiary care hospital in Greece: Incidence, risk factors, microbiology, and impact. Am J Infect Control 2008;36:732-738.
45. Lichtenstern C, Schmidt J, Knaebel HP, et al. Postoperative bacterialfungal infections: A challenging problem in critically ill patients after abdominal surgery. Dig Surg 2007; 24:1-11.
46. Livermore DM. Bacterial resistance: Origins, epidemiology, and impact. Clin Infect Dis 2003;36:11-23.
47. Poulakou G, Giamarellou H. Investigational treatments for postoperative surgical site infections. Expert Opin Investig Drugs 2007;2:137-155.
48. Bratzler DW, Houck PM, Richards C, et al. Use of antimicrobial prophylaxis for major surgery. Arch Surg 2005;140: 174-182.
49. van Hal SJ, Jennings Z, Stark D, et al. MRSA detection: Comparison of two molecular methods (BD GeneOhm-) PCR assay and Easy-Plex) with two selective MRSA agars (MRSA-ID and Oxoid MRSA) for nasal swabs. Eur J Clin Microbiol Infect Dis 2009;28:47-53.
50. Harbarth S, Fankhauser C, Schrenzel J, et al. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 2008;299:1149-1157.
51. Kitzes-Cohen R, Farin D, Piva G, et al. Pharmacokinetics of vancomycin administered as prophylaxis before cardiac surgery. Ther Drug Monit 2000;22:661-667.
52. Martin C, Alaya M, Mallet MN, et al. Penetration of vancomycin into mediastinal and cardiac tissues in humans. Antimicrob Agents Chemother 1994;38:396-399. (Pubitemid 24054274)
53. Bailey J, Summers KM. Dalbavancin: A new lipoglycopeptide antibiotic. Am J Health Syst Pharm 2008;7:599-610.